New combo therapy targets Hard-to-Treat liver cancer
NCT ID NCT04605731
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 28 times
Summary
This early-phase study tests whether giving two immunotherapy drugs (durvalumab and tremelimumab) after a type of internal radiation (radioembolization) can help control advanced liver cancer that cannot be removed by surgery. About 25 adults with locally advanced liver cancer will participate. The main goals are to check safety and see if the combination shrinks tumors or slows the cancer's growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III HEPATOCELLULAR CARCINOMA AJCC V8 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
Conditions
Explore the condition pages connected to this study.